BMO Capital Maintains Market Perform on ASGN, Lowers Price Target to $95
BMO Capital analyst Jeffrey Silber maintains ASGN (NYSE:ASGN) with a Market Perform and lowers the price target from $98 to $95.
ASGN Q3 EPS $1.79 Beats $1.78 Estimate, Sales $1.20B Beat $1.19B Estimate
ASGN (NYSE:ASGN) reported quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.78 by 0.56 percent. This is a 13.29 percent increase over earnings of $1.58 per share from the same period
ECS Wins $53M Recompete Supporting US Transportation Command’s Global Air Transportation Execution System
ECS, a leader in advanced technology, science, and digital transformation solutions, has won a five-year recompete contract valued at $53M in support of the USTRANSCOM Global Air Transportation Execution System
Recap: ASGN Q2 Earnings
ASGN (NYSE:ASGN) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
Earnings
ASGN beat estimated earnings by 3.64%, reporting an EPS of $1.71 versus an estimate of $1.65.
Earnings Scheduled For July 27, 2022
Companies Reporting Before The Bell
• Equinor (NYSE:EQNR) is projected to report earnings for its second quarter.
BMO Capital Downgrades ASGN to Market Perform, Announces $102 Price Target
BMO Capital analyst Jeffrey Silber downgrades ASGN (NYSE:ASGN) from Outperform to Market Perform and announces $102 price target.
Benzinga’s Top Ratings Upgrades, Downgrades For May 25, 2022
Upgrades
Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.